{"entity":{"type":"insider","cik":"0001297397","url":"/insider/0001297397","json_url":"/insider/0001297397.json","name":"North Bridge Venture Management V, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":13,"n_filings":4,"first":"2013-08-19","last":"2023-06-02","span_basis":"filed_date"},"name_variants":[{"name":"North Bridge Venture Management V, L.P.","source":"filing","n_filings":4,"first_seen":"2013-08-19","last_seen":"2023-06-02"}],"transactions":[{"id":7834438,"accession":"0000899243-23-014352","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-23-014352","line_url":"/filing/0000899243-23-014352","is_derivative":false,"issuer_cik":"0001138399","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001138399","owner_cik":null,"owner_name":"NBVM GP, LLC; DAMORE RICHARD A; NORTH BRIDGE VENTURE PARTNERS V A LP; North Bridge Venture Management VI, L.P.; NORTH BRIDGE VENTURE PARTNERS V-B LP; North Bridge Venture Management V, L.P.; North Bridge Venture Partners VI L P","owner_display_name":"NBVM GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1805416.0,"shares_display":"1,805,416","price_per_share":2.43,"price_display":"2.43","price_state":"stated","total_value":4387160.88,"total_display":"4,387,160.88","total_whole":"4,387,161","shares_owned_after":2521745.0,"shares_owned_after_display":"2,521,745","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-31","filed_date":"2023-06-02","scope":"insider","n_lines":3},{"id":6139627,"accession":"0000899243-22-014796","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-014796","line_url":"/filing/0000899243-22-014796","is_derivative":false,"issuer_cik":"0001138399","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001138399","owner_cik":null,"owner_name":"North Bridge Venture Management VI, L.P.; NBVM GP, LLC; DAMORE RICHARD A; NORTH BRIDGE VENTURE PARTNERS V-B LP; North Bridge Venture Management V, L.P.; NORTH BRIDGE VENTURE PARTNERS V A LP; North Bridge Venture Partners VI L P","owner_display_name":"North Bridge Venture Management VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2369667.0,"shares_display":"2,369,667","price_per_share":4.22,"price_display":"4.22","price_state":"stated","total_value":9999994.74,"total_display":"9,999,994.74","total_whole":"9,999,995","shares_owned_after":1855443.0,"shares_owned_after_display":"1,855,443","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-04-12","filed_date":"2022-04-14","scope":"insider","n_lines":3},{"id":2952700,"accession":"0000899243-20-012179","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-20-012179","line_url":"/filing/0000899243-20-012179","is_derivative":false,"issuer_cik":"0001138399","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001138399","owner_cik":null,"owner_name":"North Bridge Venture Partners VI L P; NBVM GP, LLC; NORTH BRIDGE VENTURE PARTNERS V A LP; DAMORE RICHARD A; NORTH BRIDGE VENTURE PARTNERS V-B LP; North Bridge Venture Management V, L.P.; North Bridge Venture Management VI, L.P.","owner_display_name":"North Bridge Venture Partners VI L P","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24183.0,"shares_display":"24,183","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":386928.0,"total_display":"386,928.00","total_whole":"386,928","shares_owned_after":661153.0,"shares_owned_after_display":"661,153","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-05","filed_date":"2020-05-06","scope":"insider","n_lines":3},{"id":2952687,"accession":"0000899243-20-012179","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-20-012179","line_url":"/filing/0000899243-20-012179","is_derivative":false,"issuer_cik":"0001138399","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001138399","owner_cik":null,"owner_name":"North Bridge Venture Partners VI L P; NBVM GP, LLC; NORTH BRIDGE VENTURE PARTNERS V A LP; DAMORE RICHARD A; NORTH BRIDGE VENTURE PARTNERS V-B LP; North Bridge Venture Management V, L.P.; North Bridge Venture Management VI, L.P.","owner_display_name":"North Bridge Venture Partners VI L P","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4000000.0,"total_display":"4,000,000.00","total_whole":"4,000,000","shares_owned_after":778592.0,"shares_owned_after_display":"778,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-05","filed_date":"2020-05-06","scope":"insider","n_lines":3},{"id":5448002,"accession":"0001181431-13-045521","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-045521","line_url":"/filing/0001181431-13-045521#line-1","is_derivative":false,"issuer_cik":"0001138399","issuer_name":"Demandware Inc","issuer_ticker":"DWRE","issuer_name_source":null,"issuer_url":"/issuer/0001138399","owner_cik":null,"owner_name":"NORTH BRIDGE VENTURE PARTNERS V-B LP; North Bridge Venture Management V, L.P.; ANDERSON EDWARD T; DAMORE RICHARD A; NBVM GP, LLC","owner_display_name":"NORTH BRIDGE VENTURE PARTNERS V-B LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":131.0,"shares_display":"131","price_per_share":45.55,"price_display":"45.55","price_state":"stated","total_value":5967.05,"total_display":"5,967.05","total_whole":"5,967","shares_owned_after":473902.0,"shares_owned_after_display":"473,902","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-08-15","filed_date":"2013-08-19","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001327273","name":"Lyra Therapeutics, Inc.","url":"/issuer/0001327273","role":"Ten percent owner","n_filings":3,"first_seen":"2020-05-06","last_seen":"2023-06-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001301031","name":"Demandware Inc","url":"/issuer/0001301031","role":"Ten percent owner","n_filings":1,"first_seen":"2013-08-19","last_seen":"2013-08-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001297397","retrieved_at":"2026-08-22T14:15:13+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}